All News
Filter News
Found 808,890 articles
-
Omeros is getting a lot of love from investors and analysts these days.
-
Nobody is interested in slow-growth or no-growth stocks, long term or short term, but everyone's interested in fast-growing stocks.
-
Tiny ITUS believes it is on track to develop a CAR-T treatment for solid tumors.
-
After being criticized earlier this month by U.S. Sen. Kamala Harris, three separate sexual harassment lawsuits have been reported.
-
The Medicines Company is selling its infectious disease business unit to Melinta Therapeutics.
-
The company indicates it plans to use the proceeds from the latest financing to move its lead product candidates into clinical trials and to continue developing its exosome therapeutic platform.
-
The company has snapped up manufacturing space in North Carolina's Research Triangle Park to internally produce lentiviral vector for the company's gene and cell therapies.
-
A delay in returning its Lotus Edge Aortic Valve System to the market has cost Boston Scientific an estimated $3B loss in market capitalization.
-
Regeneron and Decibel scientists will be working together, shoulder to shoulder, on project teams beginning at the earliest stages of research.
-
YmAbs Announces Closing of $30M Extension of Private Equity Placement
11/29/2017
Together, with the $50 million raised in the first closing, the Company has now raised $80 million pursuant to this private placement round.
-
Iftach Seri previously served as Sun Pharmaceutical’s head of API.
-
6 Researchers Chosen for New Pfizer-NCBiotech Distinguished Postdoctoral Fellowships in Gene Therapy
11/29/2017
The awards will enable the Fellows to conduct research in the laboratories of gene therapy-related investigators at their respective North Carolina universities. -
What many hope will be the final chapter in an unfortunate saga in multiple sclerosis research appears to have been written by the scientist who started the affair in the first place.
-
The Series A funding will be used primarily to advance Mavu's lead drug candidates into the clinic.
-
Are We Reaching the Biotech Singularity?
11/29/2017
The "singularity" is a term favored by futurists like Google exec Ray Kurzweill, typically in reference to computer technology. -
FDA Approves Ferring's CLENPIQ (Sodium Picosulfate, Magnesium Oxide, and Anhydrous Citric Acid) O...
11/29/2017
With availability planned in Q1 2018, CLENPIQ will be the only FDA-approved prescription colonoscopy prep that comes "ready-to-drink". -
Capricor Therapeutics Announces FDA Clearance of IND Application for CAP-1002
11/29/2017
This randomized, double-blind, placebo-controlled clinical trial will be called the HOPE-2 Trial.
-
Ipsen Announces Publication in Neurology of Results of Two Studies Demonstrating the Efficacy and Safety Of Dysport (Abobotulinumtoxina) in Adult Patients With Lower Limb Spasticity
11/29/2017
Results led to regulatory approval of Dysport for the treatment of lower limb spasticity in adults in the U.S. in 2017 and in some European countries in 2016.
-
Pharnext: Successful Intermediate Analyses for PLEO-CMT Phase III Clinical Trial in Charcot-Marie-Tooth Disease Type 1A
11/29/2017
PLEO-CMT study to continue as planned without increasing the number of patients.
-
Peer-Reviewed Article Published on Pluristem’s PLX-PAD Cells’ Mechanism of Action to Restore Blood Flow in Ischemic Tissue
11/29/2017
Data supports advanced PLX-PAD clinical studies including dosing regimen, systemic therapeutic effects and superiority of the cells over cytokines.